Portal de investigação
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Olivera, PA
- Zuily, S
- Kotze, PG
- Regnault, V
- Al Awadhi, S
- Bossuyt, P
- Gearry, RB
- Ghosh, S
- Kobayashi, T
- Lacolley, P
- Louis, E
- Ng, SC
- Papa, A
- Raine, T
- Teixeira, F
- Rubin, DT
- Danese, S
- Peyrin-Biroulet, L
Unidades de investigação
Abstract
Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. This Evidence-Based Guideline presents an international consensus on the prevention of venous and arterial thrombotic events in patients with IBD, and includes 19 recommendations for clinical practice. Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as 'fully agree' or 'mostly agree' with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.
Dados da publicação
- ISSN/ISSNe:
- 1759-5045, 1759-5053
- Tipo:
- Article
- Páginas:
- 857-873
- Link para outro recurso:
- www.scopus.com
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY Nature Publishing Group
Citações Recebidas na Web of Science: 52
Citações Recebidas na Scopus: 83
Documentos
- Não há documentos
Filiações
Keywords
- FACTOR-V-LEIDEN; HOSPITALIZED MEDICAL PATIENTS; NECROSIS-FACTOR-INHIBITORS; ISCHEMIC-HEART-DISEASE; RISK-ASSESSMENT MODEL; FREE PROTEIN-S; THROMBOEMBOLIC EVENTS; CARDIOVASCULAR RISK; BLEEDING RISK; EXTRAINTESTINAL MANIFESTATIONS
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Olivera PA,Zuily S,Kotze PG,Regnault V,Al Awadhi S,Bossuyt P,Gearry RB,Ghosh S,Kobayashi T,Lacolley P,Louis E,Magro F,Ng SC,Papa A,Raine T,Teixeira F,Rubin DT,Danese S,Peyrin L. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2021. 18. (12):p. 857-873. IF:73,082. (1).
